|This article is outdated. (November 2014)|
JX-594 is an oncolytic virus (also known as Pexa-Vec) developed by Jennerex and partners: Transgene S.A.; Lee's Pharmaceutical Holdings Ltd.; and Green Cross Corp. Pexa-Vec is designed to target and destroy cancer cells.
JX-594 is a vaccinia poxvirus engineered by addition of the GM-CSF gene and deletion of the thymidine kinase gene which limits viral replication to cells with high levels of thymidine kinase, typically seen in cancer cells with a mutated RAS or p53 gene. The virus kills them by lysis and also expresses GM-CSF which may help initiate an anti-tumour immune response. 
Early results, in Nov 2011, from a small (30 patient) phase II trial in advanced hepatocellular carcinoma (HCC) showed an increased median overall survival of 13.8 months compared 6.7 months for a lower dose (p=0.029).
- Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
- Un virus contre le cancer 25 March 2012, Radio Canada (French)
- Bos, JL (Sep 1, 1989). "ras oncogenes in human cancer: a review.". Cancer Research 49 (17): 4682–9. PMID 2547513.
- "NCI Drug Dictionary". National Cancer Institute. Retrieved 25 March 2013.
- "Novel Cancer-Targeting Virus Therapy Shows Efficacy in Early-Stage Trial". 31 August 2011.
- Breitbach at al. (2011). "Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans" 477 (7362). pp. 99–102. doi:10.1038/nature10358. PMID 21886163.
- http://www.voanews.com/english/news/health/Cancer-Fighting-Engineered-Virus-Makes-Medical-History-128899673.html September 01, 2011 Voice of America
- "Cancer-fighting virus shown to target tumors alone". Aug 31, 2011.
- "AASLD: Virus Shuts Down Liver Cancer in Early Trials". Nov 2011.